Business Insights, Jan 2007, Pages: 224
class
CNS sales by country
Top CNS companies
Top CNS brands
Unmet needs
Psychiatric disorders
Depression
Anxiety
Schizophrenia
Sleep disorders
Neurologic disorders
Alzheimer’s
Epilepsy
Espicom Business Intelligence Ltd, Aug 2008, Pages: 84
formulations (intramuscular, slow release) to aid compliance, new indications (major depression, anxietydisorders, autism, maintenance of bipolar disorder) and to initiate additional Phase IV trials to optimise
Espicom Business Intelligence Ltd, Aug 2008, Pages: 446
of companies focus on a diverse range of CNS disorders attempting to address unmet clinical need and large patient populations. However, in some markets such as MS, a handful of companies dominate
Frost & Sullivan, Sep 2004
comparable to leading atypical antipsychotics without causing the associated side effects. However, the newly approved indications increase the use of atypical antipsychotics for treating bipolar disorders
PharmaVision, Dec 2007, Pages: 100
“The World Health Organization has indicated that CNS disorders are the major medical challenge of the 21st Century, yet treatments for most CNS disorders are either inadequate or absent. The CNS
GlobalData, Dec 2011, Pages: 53
therapeutic landscape comprises off - label medications that treat only co - morbid conditions such as depression, anxiety, Obsessive Compulsive Disorder (OCD). The off - label medications include
